Spyglass Pharma provides medicine for ophthalmic diseases.
Spyglass Pharma has raised $75.0M in total funding. The most recent round was Series D. The last funding was announced in June 2025.
Spyglass Pharma's investors include New Enterprise Associates, RA Capital Management, Sands Capital Ventures, Samsara BioCapital, Vensana Capital.
Spyglass Pharma is headquartered in Aliso Viejo, United States.
Spyglass Pharma provides medicine for ophthalmic diseases.
Spyglass Pharma is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Spyglass Pharma — Funding & Investors." VCBacked, June 2, 2025, https://www.vcbacked.co/company/spyglass-pharma. Accessed October 30, 2026.
VCBacked. (2025). Spyglass Pharma — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/spyglass-pharma
{{cite web |title=Spyglass Pharma — Funding & Investors |url=https://www.vcbacked.co/company/spyglass-pharma |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated